Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Decreases By 61.9%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a significant decrease in short interest in December. As of December 15th, there was short interest totalling 5,300 shares, a decrease of 61.9% from the November 30th total of 13,900 shares. Based on an average daily trading volume, of 53,200 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.

Barinthus Biotherapeutics Price Performance

Shares of BRNS stock remained flat at $1.06 during trading hours on Friday. 55,114 shares of the stock were exchanged, compared to its average volume of 29,484. The firm has a market capitalization of $42.64 million, a price-to-earnings ratio of -0.71 and a beta of -0.73. Barinthus Biotherapeutics has a twelve month low of $0.80 and a twelve month high of $4.16. The firm has a fifty day moving average of $1.15 and a two-hundred day moving average of $1.28.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.23. The business had revenue of $14.97 million for the quarter. During the same period in the previous year, the firm earned ($0.37) EPS. As a group, analysts forecast that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Barinthus Biotherapeutics in a research note on Tuesday, November 19th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Alphabet Inc. purchased a new position in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,513,644 shares of the company’s stock, valued at approximately $2,119,000. Barinthus Biotherapeutics comprises 0.1% of Alphabet Inc.’s portfolio, making the stock its 29th biggest holding. Alphabet Inc. owned approximately 3.88% of Barinthus Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. 25.20% of the stock is owned by hedge funds and other institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.